Total Funding
88
20
Total FundingSeries B raised
Growth Score
-7 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
12638
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
- Ann Lee-Karlon: Chief Executive Officer and President
- James Wells: Co-FounderPast Role: Sunesis Pharmaceuticals, Founder
About the Company
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. The company provides an EpiTAC platform that enables the development of targeted therapies that degrade disease-driving membrane and extracellular proteins in a wide range of disorders.
